Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Receives Consensus Rating of “Buy” from Brokerages

Shares of Bayer Aktiengesellschaft (OTCMKTS:BAYRY – Get Free Report) have been assigned an average recommendation of “Buy” from the eight brokerages that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a hold recommendation, five have issued a buy recommendation and two have given a strong buy recommendation to the company.

Several research firms have recently weighed in on BAYRY. Deutsche Bank Aktiengesellschaft upgraded Bayer Aktiengesellschaft from a “hold” rating to a “buy” rating in a research note on Thursday, July 2nd. Zacks Research raised Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a research report on Friday, July 10th.

Get Bayer Aktiengesellschaft alerts:

Check Out Our Latest Stock Analysis on Bayer Aktiengesellschaft

Bayer Aktiengesellschaft Trading Down 1.8%

Shares of OTCMKTS BAYRY opened at $12.41 on Tuesday. The firm’s 50 day moving average price is $13.99 and its 200-day moving average price is $12.53. Bayer Aktiengesellschaft has a 52-week low of $7.48 and a 52-week high of $15.23. The company has a debt-to-equity ratio of 1.05, a quick ratio of 0.67 and a current ratio of 1.04. The company has a market cap of $48.77 billion, a PE ratio of -24.33, a P/E/G ratio of 1.90 and a beta of 0.57.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY – Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The company reported $0.29 earnings per share for the quarter, topping analysts’ consensus estimates of $0.23 by $0.06. The company had revenue of $12.53 billion during the quarter, compared to analyst estimates of $12.31 billion. Bayer Aktiengesellschaft had a negative net margin of 3.80% and a positive return on equity of 16.77%. Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.200-1.346 EPS. On average, equities research analysts expect that Bayer Aktiengesellschaft will post 1.28 EPS for the current fiscal year.

Bayer Aktiengesellschaft Company Profile

(Get Free Report)

Bayer Aktiengesellschaft is a Germany-based life science company focused on health care and agriculture. Through its Pharmaceuticals, Consumer Health and Crop Science businesses, the company develops and markets products intended to improve human health, everyday self-care and agricultural productivity.

Bayer’s Pharmaceuticals business provides prescription medicines in areas such as cardiovascular disease, women’s health, oncology and specialty medicine. Its Consumer Health division offers nonprescription products in categories including pain relief, nutritional supplements, dermatology and allergy care, with brands such as Aspirin and Claritin.

Featured Stories

• Five stocks we like better than Bayer Aktiengesellschaft
• NVIDIA’s Record High Raises a Bigger Question About How Far the Rally Can Run
• A Manufacturing Surprise Could Be a Big Win for These 2 Companies
• What a $1 Billion Chip Deal Says About Amazon’s AI Ambitions
• 3 Stocks Benefiting From AI Demand Just Announced Major Buybacks

Receive News & Ratings for Bayer Aktiengesellschaft Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer Aktiengesellschaft and related companies with MarketBeat.com's FREE daily email newsletter.